Russia's Pharmstandard Q3 sales rise 84 pct
MOSCOW Oct 25 (Reuters) - Pharmstandard, Russia's top drugmaker, said on Thursday its third-quarter sales soared 84 percent, year-on-year, boosted by an early state tender for anti-cancer drugs.
Sales totalled 14.7 billion roubles ($469.32 million) compared to 8 billion roubles in the same period of 2011, the company said in a statement.
It said sales of Johnson & Johnson's anti-cancer drug Velcade totalled 4.8 billion roubles, accounting for one third of total revenue, after the government shifted its tender to the third quarter from the fourth quarter.
As a result, total sales of third-party products soared 308 percent to stand at 8.1 billion roubles, while sales of the company's own drugs were up 8.3 percent to 6.2 billion roubles.
- Insight: How U.S. spying cost Boeing multibillion-dollar jet contract
- Exclusive: Secret contract tied NSA and security industry pioneer |
- With Fed out of the way, what's next on Wall Street?
- Yemeni al Qaeda says attack on hospital was mistake
- Insight: For Chinese farmers, a rare welcome in Russia's Far East